The Immunomodulator Platform
The immunomodulator platform is Gliknik's most clinically advanced program with two compounds in clinical safety testing in patients. These peptide drugs are currently in a standard dose-rising safety study in patients with very advanced Head and Neck Squamous Cell Carcinoma. Patients interested in learning more about the clinical trial should click here. A clinical trial in combination with autologous stem cell therapy for patients with advanced myeloma is in advanced planning and will open for recruitment in late 2010. The company expects to assess these drugs for utility in other cancers.